Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-VEGFR”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Study completedNCT00389441
What this trial is testing

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Pfizer 52
Early research (Phase 1)Study completedNCT00793975
What this trial is testing

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 37
Early research (Phase 1)Study completedNCT00786383
What this trial is testing

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

Who this might be right for
Cancer
Eli Lilly and Company 25
Testing effectiveness (Phase 2)Looking for participantsNCT05069857
What this trial is testing

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Who this might be right for
Oral Squamous Cell CarcinomaNeoadjvant TherapyAnti-PD-1+1 more
Shanghai Jiao Tong University School of Medicine 46
Testing effectiveness (Phase 2)Ended earlyNCT01784861
What this trial is testing

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Who this might be right for
AdenocarcinomaPancreatic Neoplasms
Washington University School of Medicine 23
Testing effectiveness (Phase 2)WithdrawnNCT05419817
What this trial is testing

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Who this might be right for
Recurrent Endometrial CancerSolid Tumors
Haider Mahdi
Early research (Phase 1)Study completedNCT00791570
What this trial is testing

Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy

Who this might be right for
Neovascular MaculopathyAge Related Macular Degeneration
Osaka University 17
Early research (Phase 1)Looking for participantsNCT04777994
What this trial is testing

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Who this might be right for
Advanced Solid Tumor Cancer
Calico Life Sciences LLC 248
Testing effectiveness (Phase 2)UnknownNCT06140732
What this trial is testing

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Who this might be right for
ChordomaChemotherapy Effect
Xuanwu Hospital, Beijing 30
Large-scale testing (Phase 3)Study completedNCT01235962
What this trial is testing

Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Who this might be right for
Renal Cell Carcinoma (RCC)Cancer
Novartis Pharmaceuticals 1,538
Not applicableNot Yet RecruitingNCT06708650
What this trial is testing

Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular CarcinomaRadiotherapyPD-1 Inhibitors
Guiping People's Hospital 50
Early research (Phase 1)Study completedNCT01468922
What this trial is testing

Pazopanib and ARQ 197 for Advanced Solid Tumors

Who this might be right for
Solid Tumor
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Looking for participantsNCT07049926
What this trial is testing

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 140
Testing effectiveness (Phase 2)WithdrawnNCT05039736
What this trial is testing

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Who this might be right for
Hepatocellular CarcinomaLiver Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT02484404
What this trial is testing

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Who this might be right for
Colorectal NeoplasmsBreast Neoplasms
National Cancer Institute (NCI) 268
Early research (Phase 1)Study completedNCT00782002
What this trial is testing

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 27
Testing effectiveness (Phase 2)Ended earlyNCT06006923
What this trial is testing

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Who this might be right for
MSI-H Colorectal Cancer
Anwaar Saeed 1
Not applicableUnknownNCT03129724
What this trial is testing

Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib

Who this might be right for
Kidney Neoplasms
University Hospital, Strasbourg, France 100